1. Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol. 2016; 22:1461–1476. PMID:
26819514.

2. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74:756–762. PMID:
16970019.
3. Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol. 2014; 20:2168–2175. PMID:
24605015.

4. Friedman SL. Liver fibrosis--from bench to bedside. J Hepatol. 2003; 38(Suppl 1):S38–S53. PMID:
12591185.
5. Dietrich CG, Götze O, Geier A. Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol. 2016; 22:72–88. PMID:
26755861.

6. Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician. 2011; 84:1353–1359. PMID:
22230269.
7. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020–1022. PMID:
21374666.

8. Korean Liver Cancer Study Group (KLCSG). National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015; 16:465–522. PMID:
25995680.
9. Yoon JH, Park JW, Lee JM. Noninvasive diagnosis of hepatocellular carcinoma: elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice guidelines compared with other guidelines and remaining issues. Korean J Radiol. 2016; 17:7–24. PMID:
26798212.

10. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116:1413–1419. PMID:
10348825.
11. Kwon AH, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui Y, Kamiyama Y. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. Hepatology. 1997; 25:426–429. PMID:
9021958.

12. Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med. 2007; 48:685–692. PMID:
17475954.

13. de Graaf W, van Lienden KP, van Gulik TM, Bennink RJ. (99m) Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med. 2010; 51:229–236. PMID:
20080899.
14. Ge PL, Du SD, Mao YL. Advances in preoperative assessment of liver function. Hepatobiliary Pancreat Dis Int. 2014; 13:361–370. PMID:
25100120.

15. Haimerl M, Verloh N, Fellner C, Zeman F, Teufel A, Fichtner-Feigl S, et al. MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score. Sci Rep. 2014; 4:5621. PMID:
25001391.

16. Kudo M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology. 2010; 78(Suppl 1):87–93.

17. Inoue T, Kudo M, Komuta M, Hayaishi S, Ueda T, Takita M, et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol. 2012; 47:1036–1047. PMID:
22526270.

18. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010; 255:459–466. PMID:
20413759.

19. Frydrychowicz A, Lubner MG, Brown JJ, Merkle EM, Nagle SK, Rofsky NM, et al. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging. 2012; 35:492–511. PMID:
22334493.

20. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015; 275:97–109. PMID:
25559230.

21. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol. 2007; 42:242–247. PMID:
17351431.

22. Shimizu J, Dono K, Gotoh M, Hasuike Y, Kim T, Murakami T, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci. 1999; 44:1330–1337. PMID:
10489914.
23. Schmitz SA, Mühler A, Wagner S, Wolf KJ. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol. 1996; 31:154–160. PMID:
8675423.
24. Yoon JH, Lee JM, Paek M, Han JK, Choi BI. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. Eur Radiol. 2016; 26:1775–1782. PMID:
26373756.

25. Kim JY, Lee SS, Byun JH, Kim SY, Park SH, Shin YM, et al. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents. AJR Am J Roentgenol. 2013; 201:322–331. PMID:
23883212.

26. Bae KE, Kim SY, Lee SS, Kim KW, Won HJ, Shin YM, et al. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis. 2012; 30:617–622. PMID:
23258104.

27. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2
* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007; 25:540–547. PMID:
17326089.
28. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013; 267:422–431. PMID:
23382291.

29. Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, et al. Quantitative magnetic resonance imaging of hepatic steatosis: validation in ex vivo human livers. Hepatology. 2015; 62:1444–1455. PMID:
26224591.
30. Hernando D, Wells SA, Vigen KK, Reeder SB. Effect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(
*). Magn Reson Imaging. 2015; 33:43–50. PMID:
25305414.
31. Meisamy S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011; 258:767–775. PMID:
21248233.

32. Hines CD, Frydrychowicz A, Hamilton G, Tudorascu DL, Vigen KK, Yu H, et al. T(1) independent, T(2) (
*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging. 2011; 33:873–881. PMID:
21448952.
33. Yu H, McKenzie CA, Shimakawa A, Vu AT, Brau AC, Beatty PJ, et al. Multiecho reconstruction for simultaneous water-fat decomposition and T2
* estimation. J Magn Reson Imaging. 2007; 26:1153–1161. PMID:
17896369.
34. Alústiza Echeverría JM, Castiella A, Emparanza JI. Quantification of iron concentration in the liver by MRI. Insights Imaging. 2012; 3:173–180. PMID:
22696043.

35. Garcia-Tsao G, Lim JK. Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009; 104:1802–1829. PMID:
19455106.

36. Eggers H, Brendel B, Duijndam A, Herigault G. Dual-echo Dixon imaging with flexible choice of echo times. Magn Reson Med. 2011; 65:96–107. PMID:
20860006.

37. Kukuk GM, Hittatiya K, Sprinkart AM, Eggers H, Gieseke J, Block W, et al. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. Eur Radiol. 2015; 25:2869–2879. PMID:
25903702.

38. Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, et al. Estimation of liver function using T2
* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol. 2012; 81:1460–1464. PMID:
21514080.
39. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009; 30:1042–1046. PMID:
19856436.

40. Besa C, Bane O, Jajamovich G, Marchione J, Taouli B. 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function. Magn Reson Imaging. 2015; 33:1075–1082. PMID:
26119422.

41. Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewska I, Näslund E, et al. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol. 2013; 86:20120653. PMID:
23403453.

42. Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol. 2014; 24:959–966. PMID:
24463697.

43. Haimerl M, Schlabeck M, Verloh N, Zeman F, Fellner C, Nickel D, et al. Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry. Eur Radiol. 2016; 26:1125–1133. PMID:
26186960.

44. Kamimura K, Fukukura Y, Yoneyama T, Takumi K, Tateyama A, Umanodan A, et al. Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: comparison with signal intensity-based indices. J Magn Reson Imaging. 2014; 40:884–889. PMID:
24677659.

45. Stikov N, Boudreau M, Levesque IR, Tardif CL, Barral JK, Pike GB. On the accuracy of T1 mapping: searching for common ground. Magn Reson Med. 2015; 73:514–522. PMID:
24578189.
46. Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, et al. MR relaxometry in chronic liver diseases: comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity. Eur J Radiol. 2015; 84:1459–1465. PMID:
26032126.

47. Fan ST, Wang QS, Lo CM, Tam Yu KW, Lai EC, Wong J. Evaluation of indocyanine green retention and aminopyrine breath tests in patients with malignant biliary obstruction. Aust N Z J Surg. 1994; 64:759–762. PMID:
7945083.
